4CPS-042 Apremilast in psoriatic arthritis and psoriasis: a case report

BACKGROUND: Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis (PsO). PsA is a chronic inflammatoryarthropathy that affects joints accompanied by inflammation of...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur J Hosp Pharm
Main Authors: Gonzalez, M Suarez, Melini, E Gomez, Ruiz, P Diaz, Gomez, MA Ocaña, Exposito, R Mesa, Delgado, A Montero, Alonso, J Merino
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2018
Teme:
Section 4: Clinical pharmacy services
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535203/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.133
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki